Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peptidic biofunctionalization of laser patterned dental zirconia: A biochemical-topographical approach.

Materials science & engineering. C, Materials for biological applications·2021
Same author

Confocal Scanning Microscopy in Assessment of Cardiac Allograft Rejection--A Pilot Study.

Transplantation proceedings·2015
Same author

The utility of a 'non-significant' coronary angiogram.

International journal of clinical practice·2015
Same author

Return to work after heart transplantation: the New Zealand experience.

Transplantation proceedings·2013
Same author

Bone density in heart or lung transplant recipients--a longitudinal study.

Transplantation proceedings·2013
Same author

Exploring parenthood in the New Zealand Heart Transplant Program.

Transplantation proceedings·2013

Related Experiment Video

Updated: Jul 22, 2026

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice
06:42

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice

Published on: April 16, 2018

Rapamycin in cardiovascular medicine.

P N Ruygrok1, D W Muller, P W Serruys

  • 1Green Lane Hospital, Auckland, New Zealand. PRuygrok@adhb.govt.nz

Internal Medicine Journal
|February 27, 2003
PubMed
Summary

Rapamycin (sirolimus) inhibits smooth-muscle cell proliferation, showing promise for preventing arterial re-narrowing after stenting and managing chronic rejection in heart transplants. Clinical trials suggest rapamycin-coated stents may abolish restenosis in select patients.

More Related Videos

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Experiment Videos

Last Updated: Jul 22, 2026

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice
06:42

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice

Published on: April 16, 2018

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Transplantation Immunology

Background:

  • Rapamycin (sirolimus) is a natural product that inhibits smooth-muscle cell proliferation by targeting the mTOR pathway.
  • Its anti-proliferative and anti-migratory properties suggest potential applications in cardiovascular interventions and transplant management.

Purpose of the Study:

  • To evaluate the efficacy of rapamycin in preventing restenosis after percutaneous coronary intervention.
  • To explore the role of rapamycin in managing vascular complications of chronic rejection in heart transplantation.

Main Methods:

  • Clinical trials involving rapamycin-coated stents for obstructive coronary artery lesions.
  • Animal and human studies investigating rapamycin's effects on intimal hyperplasia and allograft arterial disease.

Main Results:

  • Early clinical trials indicate rapamycin-coated stents may abolish restenosis in specific patient groups.
  • Animal studies suggest rapamycin can reduce or prevent graft loss due to intimal hyperplasia.

Conclusions:

  • Rapamycin holds significant potential for overcoming restenosis and stent thrombosis in percutaneous coronary intervention.
  • Further human studies are needed to confirm rapamycin's efficacy in preventing acute rejection and allograft arterial disease, while monitoring for potential adverse effects.